DAFTAR PUSTAKA

1. Mosayyebi A, Manes C, Carugo D, Somani BK. Advances in Ureteral Stent Design and Materials. Curr Urol Rep. 2018;19(5).
2. Aggarwal SP, Priyadarshi S, Tomar V, Yadav SS, Gangkak G, Vyas N, et al. A randomized controlled trial to compare the safety and efficacy of Tadalafil and Tamsulosin in relieving double J stent related symptoms. Adv Urol. 2015;2015.
3. Lu J, Lu Y, Xun Y, Chen F, Wang S, Cao S. Impact of Endourological procedures with or without double-J stent on sexual function: A systematic review and meta-analysis. BMC Urol. 2020;20(1):1–8.
4. Vogt B, Chokri I. Histological Inflammation in Human Ureter either Healthy or Fitted with Double-Pigtail Stent or a Thin 0.3 F Suture Thread: A Preliminary Study. Adv Urol. 2020;2020.
5. Lange D, Bidnur S, Hoag N, Chew BH. Ureteral stent-associated complications-where we are and where we are going. Nat Rev Urol [Internet]. 2015;12(1):17–25. Available from: http://dx.doi.org/10.1038/nrurol.2014.340
6. Furuta A. Comparison of inflammatory urine markers in patients with interstitial cystitis and overactive bladder. 2018;3–8.
7. Tanidir Y, Mangir N, Sahan A, Sulukaya M. Turkish version of the Ureteral Stent Symptoms Questionnaire: linguistic and psychometric validation. World J Urol. 2017;35(7):1149–54.
8. Petes C, Mariani MK, Yang Y, Grandvaux N, Gee K. Interleukin (IL)-6 inhibits IL-27- and IL-30-mediated inflammatory responses in human monocytes. Front Immunol. 2018;9(FEB):1–16.
9. Al-eisa A. Serum and Urine Interleukin-6 and Interleukin-8 Levels Do Not Differentiate Acute Pyelonephritis from Lower Urinary Tract Infections in Children. 2020;
10. Lotz M, Villiger P, Li THUG, Koziol J, W BLZ. Interleukin-6 and interstitial cystitis. 1994;152(September):869–73.
11. Tae BS, Cho S, Jeon BJ, Choi H, Park JY, Cho SY, et al. Does mirabegron relieve ureteric stent-related discomfort? A prospective, randomized, multicentre study. BJU Int. 2018;122(5):866–72.
12. Otsuki H, Yamasaki T, Hori S, Aoki H, Kosaka T, Uehara S, et al. The efficacy of mirabegron for the relief of ureteral stent-related symptoms. Acta Med Okayama. 2020;74(2):145–50.
13. Lena M Di, Tolls V, Kelly K, Nickel JC. Mirabegron as adjuvant treatment for patients with interstitial cystitis / bladder pain syndrome. 2018;12(3).
14. Navanimitkul N, Lojanapiwat B. Efficacy of tamsulosin 0.4 mg/day in relieving double-J stent-related symptoms: A randomized controlled study. J Int Med Res. 2010;38(4):1436–41.
15. Beysens M, Tailly TO. Ureteral stents in urolithiasis. Asian J Urol [Internet]. 2018;5(4):274–86. Available from: https://doi.org/10.1016/j.ajur.2018.07.002
16. Gibson W, MacDiarmid S, Huang M, Siddiqui E, Stölzel M, Choudhury N, et

al. Treating Overactive Bladder in Older Patients with a Combination of Mirabegron and Solifenacin: A Prespecified Analysis from the BESIDE Study. Eur Urol Focus. 2017;3(6):629–38.

17. Kelleher C, Hakimi Z, Zur R, Siddiqui E, Maman K, Aballéa S, et al. Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis [Figure presented]. Eur Urol. 2018;74(3):324–33.

18. Camtosun A, Bicer S. The impact of Double J stent on the quality of sexual life and job performance. Clin Exp Obstet Gynecol. 2020;47(2):199–201.

19. Zumstein V, Betschart P, Albrich WC, Buhmann MT, Ren Q, Schmid H-P, et al. Biofilm formation on ureteral stents - Incidence, clinical impact, and prevention. Swiss Med Wkly. 2017 Feb;

20. Sighinolfi MC, Sighinolfi GP, Galli E, Micali S, Ferrari N, Mofferdin A, et al. Chemical and Mineralogical Analysis of Ureteral Stent Encrustation and Associated Risk Factors. Urology. 2015;86(4):703–6.

21. Fischer KM, Louie M, Mucksavage P. Ureteral Stent Discomfort and Its Management. Curr Urol Rep. 2018;19(8):5–8.

22. Gonzalez EJ, Arms L, Vizzard MA. The Role (s) of Cytokines / Chemokines in Urinary Bladder Inflammation and Dysfunction. 2014;2014.

23. Rodhe N, Löfgren S, Strindhall J, Matussek A. Cytokines in urine in elderly subjects with acute cystitis and asymptomatic bacteriuria. 2009;3432.

24. Akdis M, Burgler S, Crameri R, Eiwegger T, Fujita H, Gomez E, et al. Interleukins, from 1 to 37, and interferon-γ: Receptors, functions, and roles in diseases. J Allergy Clin Immunol. 2011;127(3):701-721.e70.

25. Choy E. Interleukin-6 as a multifunctional regulator: inflammation, immune response, and fibrosis. 2017;2(Suppl 2):1–5.

26. White WB, Siddiqui E, Tat T, Franks B, Schermer CR. Cardiovascular safety of mirabegron: analysis of an integrated clinical trial database of patients with overactive bladder syndrome. J Am Soc Hypertens [Internet]. 2018;12(11):768-778.e1. Available from: https://doi.org/10.1016/j.jash.2018.08.001

27. Nachawati D, Patel J. Alpha Blockers. Encycl Toxicol Third Ed. 2021;

28. Robinson D, Cardozo L. Solifenacin : pharmacology and clinical efficacy. Expert Rev Clin Pharmacol. 2009;2(3):239–53.

29. Chapple CR, Siddiqui E. Mirabegron for the treatment of overactive bladder: a review of efficacy, safety and tolerability with a focus on male, elderly and antimuscarinic poor-responder populations, and patients with OAB in Asia. Expert Rev Clin Pharmacol. 2017;10(2):131–51.

30. Zhou L, Cai X, Li H, Wang K. Effects of α-Blockers, Antimuscarinics, or Combination Therapy in Relieving Ureteral Stent-Related Symptoms: A Meta-Analysis. J Endourol. 2015 Jun;29(6):650–6.

31. Liu Q, Luo D, Yang T, Liao B, Li H, Wang KJ. Protective Effects of Antimuscarinics on the Bladder Remodeling after Bladder Outlet Obstruction. Cell Physiol Biochem. 2017;44(3):907–19.

32. Wood MW, Breitschwerdt EB, Gookin JL. Autocrine effects of interleukin-6 mediate acute-phase proinflammatory and tissue-reparative transcriptional

responses of canine bladder mucosa. Infect Immun. 2011;79(2):708–15.

33. Segarra-Medrano A, Carnicer-Caceres C, Valtierra-Carmeno N, Agraz-Pamplona I, Ramos-Terrades N, Jatem Escalante E, et al. Valor de los niveles urinarios de interleucina 6, factor de crecimiento epidérmico, proteína quimioatractante de monocitos de tipo 1 y factor de crecimiento transformante β1 para la predicción de la extensión de las lesiones de fibrosis en biopsias de enf. Nefrología [Internet]. 2017;37(5):531–8. Available from: http://dx.doi.org/10.1016/j.nefro.2016.11.017

34. Grover S, Srivastava A, Lee R, Tewari AK, te AE. Role of inflammation in bladder function and interstitial cystitis. Ther Adv Urol. 2011;3(1):19–33.

35. Alexander K, Palinrungi A, Palinrungi M, Kholis K, Syahrir S, Syarif S, Faruk M (2020) Effectiveness of Tamsulosin compared with Mirabegron in treatment of Double-J Stent-Related Lower Urinary Tract Symptoms. Int J Med Rev Case Reports 4:8–13

36. Yavuz A, Kilinc MF, Aydin M, Ofluoglu Y, Bayar G (2020) Does tamsulosin or mirabegron improve ureteral stent-related symptoms? A prospective placebo-controlled study. Low Urin Tract Symptoms 1–5

37. Hasbi BE, Palinrungi MA, Kholis K, Bakri S, Syahrir S, Kasim F (2021) The Effectiveness Between Tamsulosin and Solifenacin Combined with Tamsulosin on Treatment of Ureteral Stent-Related Symptoms. Nusant Med Sci J 6:1–17

38. Ilyas MRF, Kholis K, Palinrungi MA, Palinrungi AM, Seweng A, Syahrir S, Syarif, Faruk M (2021) Comparative effectiveness of Tamsulosin and Tadalafil therapy in ureteral stents-related symptoms (uSRS). Med Clin Pract 4:1–5

39. Singh R, Bhangu GS, Bansal D, Rattan A (2021) Effect of tamsulosin on ureteric stent related morbidity: a double-blind randomized placebo-controlled study. Int Surg J 8:294–299

40. Archer M, Dogra N, Dovey Z, et al. (2021) Role of α- and β-adrenergic signaling in phenotypic targeting: significance in benign and malignant urologic disease. Cell Commun Signal 19:1–21

41. Todorova VB, Baxan N, Delahaye M, Harding SE, Rankin SM (2023) Drug-based mobilisation of mesenchymal stem/stromal cells improves cardiac function post myocardial infarction. Dis Model Mech 16:1–10

42. Kovács ZZA, Szűcs G, Freiwan M, et al. (2021) Comparison of the antiremodeling effects of losartan and mirabegron in a rat model of uremic cardiomyopathy. Sci Rep 11:1–18

43. da Silva CPV, Calmasini F, Alexandre EC, Raposo HF, Delbin MA, Monica FZ, Zanesco A (2021) The effects of mirabegron on obesity-induced inflammation and insulin resistance are associated with brown adipose tissue activation but not beiging in the subcutaneous white adipose tissue. Clin Exp Pharmacol Physiol 48:1477–1487

44. Ateyah MA, Abdulridha MK, Alkabee MJ (2021) Effects of Saw Palmetto Therapy on some Inflammatory Biomarkers in a Sample of Iraqi Male with Symptomatic Benign Prostatic Hyperplasia. Al Mustansiriyah J Pharm Sci 21:1–9

45. Sun L, Sun C, Zhou S, Zhang L, Hu W (2021) Tamsulosin attenuates high

glucose- induced injury in glomerular endothelial cells. Bioengineered 12:5184–5194

46. Ye Y, Xu Q, Wan M (2021) Tamsulosin combined with levofloxacin can effectively improve the clinical symptoms and reduce inflammation in CP/CPPS patients. Int J Clin Exp Med 14:326–332

47. Bantis A, Tsakaldimis G, Zissimopoulos A, Giannakopoulos S, Kalaitzis C, Pitiakoudis M, Polichronidis A, Touloupidis S (2014) Can Tumor Necrosis Factor- α and Interleukin-6 Be Used as Prognostic Markers of Infection following Ureteroscopic Lithotripsy? ISRN Urol 2014:1–5

48. Cinar O, Tanidir Y, Ozer S, et al. (2020) Effects of mirabegron on JJ stent-related symptoms: A multicentric study. Int J Clin Pract 00:1–5

49. Wang W, Jian B, Qiao S, Ji J, Wang L (2018) Effect of Tamsulosin on the Patients with Lower Ureteral Stones after Extracorporeal Shock Wave Lithotripsy and Serum Levels of IL-6, IL-10 and CRP. Prog Mod Biomed 18:4099–4102

50. Niemczyk G, Fus L, Czarzasta K, Jesion A, Radziszewski P, Gornicka B, Cudnoch-Jedrzejewska A (2020) Expression of Toll-Like Receptors in the Animal Model of Bladder Outlet Obstruction. Biomed Res Int. https://doi.org/10.1155/2020/6632359

51. Zhang K, Yan W, Li H, Chen J, Wang Q, Chai Y, Yuan L, Zhu G (2022) Comparison of Mirabegron plus Tamsulosin and Tamsulosin Monotherapy for the Treatment of Ureteral Stent-Related Symptoms: A Prospective Randomized Study. Urol Int 106:1226–1232

Lampiran Tabel 1

Statistics

		Jenis Kelamin	IMT	Suku	PKJ kode
N	Valid	20	20	20	20
	Missing	0	0	0	0

Jenis Kelamin

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Perempuan	10	50,0	50,0	50,0
	Laki-laki	10	50,0	50,0	100,0
	Total	20	100,0	100,0	

IMT

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Kurang (<18,5)	2	10,0	10,0	10,0
	Baik (18,5-24,9)	11	55,0	55,0	65,0
	Obesitas (>25)	7	35,0	35,0	100,0
	Total	20	100,0	100,0	

Suku

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Bugis	16	80,0	80,0	80,0
	Banjar	2	10,0	10,0	90,0
	Toraja	2	10,0	10,0	100,0
	Total	20	100,0	100,0	

PKJ kode

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	IRT	9	45,0	45,0	45,0
	Wiraswasta	3	15,0	15,0	60,0
	Karyawan	3	15,0	15,0	75,0
	PNS	1	5,0	5,0	80,0
	Pensiunan	2	10,0	10,0	90,0
	Petani	1	5,0	5,0	95,0
	Ojek	1	5,0	5,0	100,0
	Total	20	100,0	100,0	

Tests of Normality

	Kolmogorov-Smirnov[a]			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
Umur	,210	20	,021	,899	20	,040

a. Lilliefors Significance Correction

Descriptives

			Statistic	Std. Error
Umur	Mean		43,60	2,981
	95% Confidence Interval for Mean	Lower Bound	37,36	
		Upper Bound	49,84	
	5% Trimmed Mean		43,78	
	Median		42,00	
	Variance		177,726	
	Std. Deviation		13,331	
	Minimum		23	
	Maximum		61	
	Range		38	
	Interquartile Range		21	
	Skewness		-,185	,512
	Kurtosis		-1,448	,992

Lampiran Tabel 2

Tests of Normality

	Kolmogorov-Smirnov[a]			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
Umur	,210	20	,021	,899	20	,040

a. Lilliefors Significance Correction

Descriptives

			Statistic	Std. Error
Umur	Mean		43,60	2,981
	95% Confidence Interval for Mean	Lower Bound	37,36	
		Upper Bound	49,84	
	5% Trimmed Mean		43,78	
	Median		42,00	
	Variance		177,726	
	Std. Deviation		13,331	
	Minimum		23	
	Maximum		61	
	Range		38	
	Interquartile Range		21	
	Skewness		-,185	,512
	Kurtosis		-1,448	,992

Jenis Kelamin

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Perempuan	10	50,0	50,0	50,0
	Laki-laki	10	50,0	50,0	100,0
	Total	20	100,0	100,0	

IMT

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Kurang (<18,5)	2	10,0	10,0	10,0
	Baik (18,5-24,9)	11	55,0	55,0	65,0
	Obesitas (>25)	7	35,0	35,0	100,0
	Total	20	100,0	100,0	

Suku

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Bugis	16	80,0	80,0	80,0
	Banjar	2	10,0	10,0	90,0
	Toraja	2	10,0	10,0	100,0
	Total	20	100,0	100,0	

PKJ kode

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	IRT	9	45,0	45,0	45,0
	Wiraswasta	3	15,0	15,0	60,0
	Karyawan	3	15,0	15,0	75,0
	PNS	1	5,0	5,0	80,0
	Pensiunan	2	10,0	10,0	90,0
	Petani	1	5,0	5,0	95,0
	Ojek	1	5,0	5,0	100,0
	Total	20	100,0	100,0	

Crosstab

			Obat		Total
			Mirabegron	Tamsulosin	
Jenis Kelamin	Perempuan	Count	6	4	10
		% within Obat	60,0%	40,0%	50,0%
	Laki-laki	Count	4	6	10
		% within Obat	40,0%	60,0%	50,0%
Total		Count	10	10	20
		% within Obat	100,0%	100,0%	100,0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	,800[a]	1	,371		
Continuity Correction[b]	,200	1	,655		
Likelihood Ratio	,805	1	,369		
Fisher's Exact Test				,656	,328
Linear-by-Linear Association	,760	1	,383		
N of Valid Cases	20				

a. 0 cells (0,0%) have expected count less than 5. The minimum expected count is 5,00.

b. Computed only for a 2x2 table

Tests of Normality

	Obat	Kolmogorov-Smirnov[a]			Shapiro-Wilk		
		Statistic	df	Sig.	Statistic	df	Sig.
Umur	Mirabegron	,240	10	,108	,902	10	,229
	Tamsulosin	,189	10	,200[*]	,875	10	,113

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

Group Statistics

	Obat	N	Mean	Std. Deviation	Std. Error Mean
Umur	Mirabegron	10	45,00	12,454	3,938
	Tamsulosin	10	42,20	14,688	4,645

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means						
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	95% Confidence Interval of the Difference Lower	95% Confidence Interval of the Difference Upper
Umur	Equal variances assumed	,277	,605	,460	18	,651	2,800	6,090	-9,994	15,594
	Equal variances not assumed			,460	17,532	,651	2,800	6,090	-10,019	15,619

Crosstab

			Obat		
			Mirabegron	Tamsulosin	Total
IMT	Kurang (<18,5)	Count	2	0	2
		% within Obat	20,0%	0,0%	10,0%
	Baik (18,5-24,9)	Count	5	6	11
		% within Obat	50,0%	60,0%	55,0%
	Obesitas (>25)	Count	3	4	7
		% within Obat	30,0%	40,0%	35,0%
Total		Count	10	10	20
		% within Obat	100,0%	100,0%	100,0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)
Pearson Chi-Square	2,234[a]	2	,327
Likelihood Ratio	3,007	2	,222
Linear-by-Linear Association	1,103	1	,294
N of Valid Cases	20		

a. 4 cells (66,7%) have expected count less than 5. The minimum expected count is 1,00.

Crosstab

			Obat		
			Mirabegron	Tamsulosin	Total
PKJ kode	IRT	Count	5	4	9
		% within Obat	50,0%	40,0%	45,0%
	Wiraswasta	Count	3	0	3
		% within Obat	30,0%	0,0%	15,0%
	Karyawan	Count	0	3	3
		% within Obat	0,0%	30,0%	15,0%
	PNS	Count	0	1	1
		% within Obat	0,0%	10,0%	5,0%
	Pensiunan	Count	1	1	2
		% within Obat	10,0%	10,0%	10,0%
	Petani	Count	0	1	1
		% within Obat	0,0%	10,0%	5,0%
	Ojek	Count	1	0	1

		% within Obat	10,0%	0,0%	5,0%
Total		Count	10	10	20
		% within Obat	100,0%	100,0%	100,0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)
Pearson Chi-Square	9,111a	6	,167
Likelihood Ratio	12,588	6	,050
Linear-by-Linear Association	,344	1	,557
N of Valid Cases	20		

a. 14 cells (100,0%) have expected count less than 5. The minimum expected count is ,50.

Crosstab

			Obat		
			Mirabegron	Tamsulosin	Total
Suku	Bugis	Count	8	8	16
		% within Obat	80,0%	80,0%	80,0%
	Banjar	Count	2	0	2
		% within Obat	20,0%	0,0%	10,0%
	Toraja	Count	0	2	2
		% within Obat	0,0%	20,0%	10,0%
Total		Count	10	10	20
		% within Obat	100,0%	100,0%	100,0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)
Pearson Chi-Square	4,000a	2	,135
Likelihood Ratio	5,545	2	,063
Linear-by-Linear Association	,463	1	,496
N of Valid Cases	20		

a. 4 cells (66,7%) have expected count less than 5. The minimum expected count is 1,00.

Lampiran Tabel 3

Descriptives

IL-6 serum pre stent ureter	Mirabegron	Mean	2,104370470933934	,393375490166099
		95% Confidence Interval for Mean	Lower Bound	1,214493288185438	
			Upper Bound	2,994247653682430	
		5% Trimmed Mean	2,074559860981391	
		Median	1,839399660056303	
		Variance	1,547	
		Std. Deviation	1,243962524610041	
		Minimum	,622208798013647	
		Maximum	4,123123123000000	
		Range	3,500914324986353	
		Interquartile Range	2,078555548919548	
		Skewness	,299	,687
		Kurtosis	-1,626	1,334
IL-6 serum post stent ureter	Mirabegron	Mean	,980998876575459	,194522761159853
		95% Confidence Interval for Mean	Lower Bound	,540957819090413	
			Upper Bound	1,421039934060504	
		5% Trimmed Mean	,959135056028287	
		Median	,944420008067538	
		Variance	,378	
		Std. Deviation	,615134982010072	
		Minimum	,232423423000000	
		Maximum	2,123123100000000	
		Range	1,890699677000000	
		Interquartile Range	1,061587932226972	
		Skewness	,537	,687
		Kurtosis	-,642	1,334

Test Statistics[a]

Obat		IL-6 serum Operasi I – IL-6 serum Operasi II
Mirabegron	Z	-2,803[b]
	Asymp. Sig. (2-tailed)	,005

a. Wilcoxon Signed Ranks Test

b. Based on positive ranks.

Lampiran Tabel 4

IL-6 serum pre stent ureter	Tamsulosin	Mean		2,032270874947530	,530637904781076
		95% Confidence Interval for Mean	Lower Bound	,831884537794787	
			Upper Bound	3,232657212100273	
		5% Trimmed Mean		1,873301728823726	
		Median		1,406434576956139	
		Variance		2,816	
		Std. Deviation		1,678024391927752	
		Minimum		,502072890608204	
		Maximum		6,423913489515340	
		Range		5,921840598907136	
		Interquartile Range		1,319565010635070	
		Skewness		2,322	,687
		Kurtosis		6,117	1,334

IL-6 serum post stent ureter	Tamsulosin	Mean		4,378156240816292	,839191185835194
		95% Confidence Interval for Mean	Lower Bound	2,479773888822089	
			Upper Bound	6,276538592810495	
		5% Trimmed Mean		4,366993777275975	
		Median		5,238298288699999	
		Variance		7,042	
		Std. Deviation		2,653755539576844	

Minimum	,723002485358285	
Maximum	8,234234340000000	
Range	7,511231854641715	
Interquartile Range	4,767222215918944	
Skewness	-,092	,687
Kurtosis	-1,568	1,334

Test Statistics[a]

Obat		IL-6 serum Operasi I – IL-6 serum Operasi II
Tamsulosin	Z	-2,701[c]
	Asymp. Sig. (2-tailed)	,007

a. Wilcoxon Signed Ranks Test
b. Based on positive ranks.

Lampiran Tabel 5

IL-6 Urine pre stent ureter	Mirabegron	Mean		28,233028454870272	20,559186619605804
		95% Confidence Interval for Mean	Lower Bound	-18,275082817976020	
			Upper Bound	74,741139727716560	
		5% Trimmed Mean		19,932194059640604	
		Median		2,079358376013585	
		Variance		4226,802	
		Std. Deviation		65,013856558412100	
		Minimum		,754478804583476	
		Maximum		205,126597219291000	
		Range		204,372118414707530	
		Interquartile Range		17,903616973984718	
		Skewness		2,743	,687
		Kurtosis		7,687	1,334

IL-6 Urine post	Mirabegron	Mean		53,814844795432620	19,391123443028754
		95% Confidence Interval for Mean	Lower Bound	9,949076004080930	

86

stent ureter		Upper Bound	97,680613586784320	
	5% Trimmed Mean		51,435046620765400	
	Median		17,928483321104054	
	Variance		3760,157	
	Std. Deviation		61,320116469457176	
	Minimum		,449063248680019	
	Maximum		150,016993486195360	
	Range		149,567930237515360	
	Interquartile Range		114,545058504486320	
	Skewness		,636	,687
	Kurtosis		-1,620	1,334

Test Statistics[a]

Obat		IL-6 Urine Operasi I – IL-6 Urine Operasi II
Mirabegron	Z	-1,580[c]
	Asymp. Sig. (2-tailed)	,114

a. Wilcoxon Signed Ranks Test

b. Based on positive ranks.

Lampiran Tabel 6

IL-6 Urine pre stent ureter	Tamsulosin	Mean		4,403801446096930	,807768601608361
		95% Confidence Interval for Mean	Lower Bound	2,576501918085086	
			Upper Bound	6,231100974108774	
		5% Trimmed Mean		4,416691271160063	
		Median		4,538066535601001	
		Variance		6,525	
		Std. Deviation		2,554388603451572	
		Minimum		,624259448347163	
		Maximum		7,951326592710300	
		Range		7,327067144363137	
		Interquartile Range		4,666589195150616	
		Skewness		-,087	,687
		Kurtosis		-1,596	1,334

IL-6 Urine post stent ureter	Tamsulosin	Mean		30,503758128737520	18,076594571322154
		95% Confidence Interval for Mean	Lower Bound	-10,388339759778045	
			Upper Bound	71,395856017253080	
		5% Trimmed Mean		25,281657117574657	
		Median		4,878844400670000	
		Variance		3267,633	
		Std. Deviation		57,163211184813050	
		Minimum		,778388969095970	
		Maximum		154,226945489310570	
		Range		153,448556520214600	
		Interquartile Range		33,107837931228070	
		Skewness		1,854	,687
		Kurtosis		1,947	1,334

Test Statistics[a]

Obat		IL-6 Urine Operasi I – IL-6 Urine Operasi II
Tamsulosin	Z	-,051[c]
	Asymp. Sig. (2-tailed)	,959

a. Wilcoxon Signed Ranks Test
b. Based on positive ranks.

Lampiran Tabel 7

Test Statistics[a]

	IL-6 serum pre stent ureter	IL-6 serum post stent ureter
Mann-Whitney U	48,000	11,000
Wilcoxon W	103,000	66,000
Z	-,151	-2,948
Asymp. Sig. (2-tailed)	,880	,003
Exact Sig. [2*(1-tailed Sig.)]	,912[b]	,002[b]

a. Grouping Variable: Obat

b. Not corrected for ties.

Lampiran Tabel 8

Test Statistics[a]

	IL-6 Urine Operasi I	IL-6 Urine Operasi II
Mann-Whitney U	35,000	38,000
Wilcoxon W	90,000	93,000
Z	-1,134	-,907
Asymp. Sig. (2-tailed)	,257	,364
Exact Sig. [2*(1-tailed Sig.)]	,280[b]	,393[b]

a. Grouping Variable: Obat

b. Not corrected for ties.

Lampiran Tabel 9

Tests of Normality

	Obat	Kolmogorov-Smirnov[a]			Shapiro-Wilk		
		Statistic	df	Sig.	Statistic	df	Sig.
Delta serum	Mirabegron	,195	10	,200*	,883	10	,140
	Tamsulosin	,174	10	,200*	,946	10	,622
Delta urine	Mirabegron	,257	10	,060	,906	10	,255
	Tamsulosin	,465	10	,000	,557	10	,000

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

Descriptives

Obat			Statistic	Std. Error
Delta serum	Mirabegron	Mean	-1,123371594400000	,225613348125089
		95% Confidence Interval for Mean	Lower Bound	-1,633744445884055	
			Upper Bound	-,612998742915945	
		5% Trimmed Mean	-1,128972225166667	
		Median	-,888925218000000	
		Variance	,509	
		Std. Deviation	,713452050611760	
		Minimum	-2,009891928000000	
		Maximum	-,136039907000000	
		Range	1,873852021000000	
		Interquartile Range	1,413128426250000	
		Skewness	-,208	,687
		Kurtosis	-1,662	1,334
	Tamsulosin	Mean	2,345885365700000	,603958138480810
		95% Confidence Interval for Mean	Lower Bound	,979637136705366	
			Upper Bound	3,712133594694635	
		5% Trimmed Mean	2,329381562000000	
		Median	2,314175441000000	

Variance	3,648	
Std. Deviation	1,909883328994746	
Minimum	-,340502727000000	
Maximum	5,329341925000000	
Range	5,669844651999999	
Interquartile Range	3,377123154000000	
Skewness	,104	,687
Kurtosis	-1,410	1,334

Test Statistics[a]

	Delta serum
Mann-Whitney U	1,000
Wilcoxon W	56,000
Z	-3,705
Asymp. Sig. (2-tailed)	,000
Exact Sig. [2*(1-tailed Sig.)]	,000[b]

a. Grouping Variable: Obat

b. Not corrected for ties.

Lampiran Tabel 10

Delta urine	Mirabegron	Mean		25,581816344600000	22,927898398143956
		95% Confidence Interval for Mean	Lower Bound	-26,284693244670848	
			Upper Bound	77,448325933870850	
		5% Trimmed Mean		26,515608649555556	
		Median		3,638025696500000	
		Variance		5256,885	
		Std. Deviation		72,504380899061000	
		Minimum		-114,631429900000000	
		Maximum		148,986801100000000	
		Range		263,618231000000040	
		Interquartile Range		83,157254035750000	
		Skewness		-,079	,687
		Kurtosis		1,017	1,334

Tamsulosin	Mean		26,099956681000002	18,074512136961538
	95% Confidence Interval for Mean	Lower Bound	-14,787430413710638	
		Upper Bound	66,987343775710640	
	5% Trimmed Mean		20,694351388444446	
	Median		-,576836610000000	
	Variance		3266,880	
	Std. Deviation		57,156625949155710	
	Minimum		-3,063509872000000	
	Maximum		152,564318500000000	
	Range		155,627828372000000	
	Interquartile Range		30,951784962250002	
	Skewness		1,889	,687
	Kurtosis		2,179	1,334

Test Statistics[a]

	Delta urine
Mann-Whitney U	34,000
Wilcoxon W	89,000
Z	-1,209
Asymp. Sig. (2-tailed)	,226
Exact Sig. [2*(1-tailed Sig.)]	,247[b]

a. Grouping Variable: Obat

b. Not corrected for ties.